« Back
Home /
DCC2036

DCC2036

Manufacturer	TargetMol
Category	Oncology Reagents & Chemicals Molecules By Organ Heart & Blood Cancer
Type	Molecules
Specific against	other
Amount	2mg
Item no.	TMO-T2640-2mg
Targets	BCR
CASRN	1020172-07-9
eClass 6.1	32169090
eClass 9.0	32169090
Available
Short Description	DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.
Shipping	cool pack
Storage	-20°
Target names or alias	DCC 2036 , DCC2036 , DCC-2036
Molecular Weight	553, 59
Pathway	Tyrosine Kinase/Adaptors\|\|\|Cytoskeletal Signaling\|\|\|Apoptosis\|\|\|Angiogenesis
Target	Bcr-Abl\|\|\|FLT\|\|\|Src\|\|\|Apoptosis

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 2mg

available

Delivery expected until 5/23/2024